Ziftomenib + Ven/Aza in Newly Diagnosed NPM1-m AML - In newly diagnosed NPM1-m AML patients, the combination of ziftomenib 600 mg QD with Ven/Aza resulted in a composite complete remission (CRc) rate of 86% (32/37), with a complete remission (CR) rate of 73% (27/37)[35] - Among CRc responders in newly diagnosed NPM1-m AML, 68% (17/25) achieved MRD negativity at a threshold of ≤01% and 44% (11/25) at a threshold of ≤001%[36] - In newly diagnosed NPM1-m AML, 68% (27/40) of patients remained alive and continued on study after a median follow-up of 261 weeks[40] Ziftomenib + Ven/Aza in R/R NPM1-m or KMT2A-r AML - In R/R NPM1-m AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an overall response rate (ORR) of 65% (31/48) and a CRc rate of 48% (23/48)[57] - In R/R KMT2A-r AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an ORR of 41% (13/32) and a CRc rate of 28% (9/32)[57] - Among R/R NPM1-m AML patients without prior venetoclax exposure, the CRc rate was 70% (16/23) and the ORR was 83% (19/23)[58] - Among R/R KMT2A-r AML patients without prior venetoclax exposure, the CRc rate was 60% (6/10) and the ORR was 70% (7/10)[58] - For R/R NPM1-m AML, the median duration of CRc was 399 weeks after a median follow-up of 274 weeks[61] - For R/R KMT2A-r AML, the median duration of CRc was 124 weeks after a median follow-up of 169 weeks[64]

Core Insights - The combination of ziftomenib with venetoclax and azacitidine shows promising clinical activity in treating acute myeloid leukemia (AML) with NPM1 mutations and KMT2A rearrangements, with high rates of complete remission and molecular negativity [2][3][8] Group 1: Clinical Efficacy - In newly diagnosed NPM1-m AML, 86% achieved composite complete remission (CRc) and 73% achieved complete remission (CR), with 68% of CRc responders attaining molecular minimal residual disease (MRD) negativity [1][2] - In relapsed/refractory (R/R) NPM1-m AML, the overall response rate (ORR) was 65%, and in venetoclax-naïve patients, the ORR was 83% [1][2] - For R/R KMT2A-r AML, the ORR was 41%, with 70% in venetoclax-naïve patients [1][2] Group 2: Safety Profile - The triplet combination of ziftomenib, venetoclax, and azacitidine was well tolerated, with low rates of ziftomenib-related myelosuppression and no increase in toxicity beyond venetoclax/azacitidine alone [1][4][7] - Adverse reactions included differentiation syndrome and QTc prolongation, but these were managed without treatment discontinuation [4][7] Group 3: Ongoing Development - Kura Oncology is conducting registrational trials for ziftomenib in both intensive chemotherapy-eligible and -ineligible patients [1][2][8] - The ongoing KOMET-007 Phase 1a/1b trial is evaluating ziftomenib's efficacy across multiple AML subtypes, reinforcing its potential as a foundational treatment option [1][8][12] Group 4: Company Information - Kura Oncology is focused on precision medicines for cancer treatment, with KOMZIFTI (ziftomenib) being the first oral menin inhibitor approved for adult patients with R/R AML harboring NPM1 mutations [12][28] - Kyowa Kirin collaborates with Kura Oncology, emphasizing their commitment to innovative treatments for high unmet medical needs [29]

Core Insights - The article highlights the identification of Kura Oncology as a promising small-cap biotech opportunity following the author's successful investment in Nuvation Bio, emphasizing the search for reasonably priced companies with long-term growth potential [1]. Group 1: Company Analysis - Kura Oncology is positioned as a small-cap biotech firm that may offer exponential growth potential, aligning with the author's investment strategy focused on fundamental analysis of businesses, financials, and valuations [1]. - The author expresses a belief that educated investors can outperform the market by understanding basic accounting and financial principles, which is relevant for evaluating companies like Kura Oncology [1]. Group 2: Investment Strategy - The investment strategy involves identifying companies that are reasonably priced and have steady long-term growth prospects, which is a key focus for the author in their analysis of Kura Oncology [1]. - The article suggests that small- and mid-cap companies, such as Kura Oncology, can present significant investment opportunities if analyzed correctly [1].

Core Viewpoint - Kura Oncology is hosting a virtual analyst and investor event on December 8, 2025, to discuss data on the triplet combination of ziftomenib, venetoclax, and azacitidine for treating acute myeloid leukemia [1][2] Company Overview - Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cancer signaling pathways and addressing hematologic malignancies and solid tumors [3] - The company has developed KOMZIFTI™, an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [3]

Core Insights - The article highlights the background and expertise of Brendan, who has a strong foundation in organic synthesis and experience in both pharmaceutical and biotech sectors [1] Group 1: Background and Experience - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - His experience includes working with biotech startups such as Theravance and Aspira before joining Caltech [1] Group 2: Entrepreneurial Ventures - Brendan was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the 8 figures [1] - He remains an active investor, focusing on market trends, particularly in biotechnology stocks [1]

Core Insights - Kura Oncology has completed its first U.S. commercial sale of KOMZIFTI™ (ziftomenib), marking a significant milestone for the company [1] - The sale triggers a $135 million milestone payment from Kyowa Kirin, expected to be received by Kura before year-end [1] - KOMZIFTI was approved by the U.S. FDA on November 13, 2025, for treating adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [1][2] Company Overview - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [2] - The company is commercializing KOMZIFTI™, a once-daily oral menin inhibitor, and is advancing research in menin inhibition and farnesyl transferase inhibition [2]

Core Insights - KOMZIFTI (ziftomenib) is the first and only once-daily oral menin inhibitor approved by the FDA for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation, now commercially available in the U.S. [1][2] - The drug has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a Category 2A recommended treatment option for this patient population [1][3] Company Overview - Kura Oncology, Inc. is a biopharmaceutical company focused on precision medicines for cancer treatment, with KOMZIFTI being a key product in its pipeline [19] - Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company with a long history in drug discovery and biotechnology innovation, collaborating with Kura on the commercialization of KOMZIFTI [20] Clinical Data - KOMZIFTI received full FDA approval on November 13, 2025, based on the KOMET-001 clinical trial, which demonstrated a 21.4% complete response (CR) or complete response with partial hematologic recovery (CRh) rate and a median duration of response of 5 months [2] - The clinical trial involved 112 patients with R/R AML and NPM1 mutation, with differentiation syndrome (DS) occurring in 26% of patients [8][14] Treatment Guidelines - The inclusion of KOMZIFTI in the NCCN Guidelines highlights its potential impact on patients with R/R NPM1-mutated AML and reflects the commitment to patient access [3] - KOMZIFTI is also being developed for front-line treatment of AML with various mutations, indicating its potential to benefit a broader patient population [5] Safety Information - KOMZIFTI has a boxed warning for differentiation syndrome, which can be fatal, and requires monitoring and management protocols [6][7] - Adverse reactions reported in clinical trials include serious reactions in 79% of patients, with the most common being infections and differentiation syndrome [14][16]

Core Viewpoint - Kura Oncology has received FDA approval for ziftomenib, marking a significant milestone for the company in its oncology portfolio [1]. Group 1: Company Overview - The conference call is led by Greg Mann, Senior Vice President of Investor Relations and Corporate Affairs at Kura Oncology [1]. - Key executives participating in the call include Dr. Troy Wilson (President and CEO), Dr. Mollie Leoni (Chief Medical Officer), and Brian Powl (Chief Commercial Officer) [2]. Group 2: FDA Approval Details - The call is focused on discussing the FDA approval of ziftomenib, with supporting materials available on the company's website [1]. - Dr. Eunice Wang, a notable expert in leukemia, is a guest speaker for the call, indicating the importance of the approval in the context of leukemia treatment [2].

Kura Oncology Conference Call Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Industry**: Oncology, specifically focusing on Acute Myeloid Leukemia (AML) treatments Key Points FDA Approval and Product Launch - Kura Oncology received FDA approval for its menin inhibitor, Zypto, targeting the relapse/refractory (R/R) AML population with NPM1 mutations, marking a significant milestone for the company [3][43] - The company emphasizes the importance of menin inhibitors in AML, stating they are the most significant advancement in the field in two decades [3][43] Efficacy and Safety - Kura's menin inhibitor is compared to two other approved agents for NPM1 mutant AML, noting that while both have good activity, Kura's product shows better duration of response [3][43] - Kura's Zypto has a mean QT prolongation of 7.7 milliseconds, significantly lower than the competitor's 23 milliseconds, which poses a higher risk of sudden cardiac death [4][44][45] - Zypto does not have clinically meaningful drug-drug interactions, unlike its competitor, which has a sensitive CYP3A4 interaction requiring dose adjustments [5][19][45] Market Potential - The total addressable market (TAM) for Zypto in the NPM1 relapse refractory setting is estimated at $350 to $400 million, with a patient population of 1,000 to 2,000 and an average treatment duration of six months [6][46] - Kura is conservative in its estimates, assuming a 50% market share, but anticipates potential upside as off-label usage and longer treatment durations are expected to increase [9][49] Competitive Landscape - Kura faces competition not only from other menin inhibitors but also from venetoclax, IDH inhibitors, and gilteritinib, particularly in the context of co-mutations in NPM1 mutant patients [7][47] - The company plans to present data at the upcoming ASH conference, which will include frontline combination studies with venetoclax and Zypto [7][48] Future Outlook - Kura is optimistic about the uptake of menin inhibitors in the market, attributing some of the awareness to the competitor's efforts [25] - The company is preparing for a potential first-line indication, which could significantly expand the market opportunity, estimating a peak potential of $10 billion annually across 10,000 to 12,000 patients [41][41] Clinical Trials and Data - Kura is conducting randomized trials to gather data that could support accelerated approval pathways, with top-line results expected in 2028 [27][28] - The company is focused on achieving MRD negativity in patients, which is a strong surrogate for survival and could influence treatment decisions regarding transplant options [39][40] NCCN Guidelines and Commercial Readiness - Kura is on track for NCCN guideline inclusion but acknowledges that the committee's decisions are outside their control [22][23] - The company has been ready for the product launch for two months and expects to see initial sales growth, although they anticipate that sales will not be material until after the holiday season [24][23] Additional Insights - Kura's conservative approach to revenue and enrollment is a key part of its strategy, aiming to underpromise and overdeliver [6][46] - The company is focused on educating physicians about the benefits of early combination therapy to optimize patient outcomes [8][48]

Kura Oncology Conference Call Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Product**: Komzifti (ziftomenib) - **Industry**: Oncology, specifically focusing on acute myeloid leukemia (AML) Key Points FDA Approval - The FDA granted full approval for Komzifti, a once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, marking a significant milestone for Kura Oncology [4][30] - The approval was ahead of the PDUFA target action date of November 30, 2025, indicating a strong benefit-risk profile for patients [4][30] Clinical Data - Komzifti demonstrated a 21.4% complete remission (CR) plus complete remission with partial hematologic recovery (CRh) rate in a study of 112 patients [10] - The median duration of response was five months, with a median time to response of 2.7 months [10] - Patients who achieved a response had a median overall survival of 18.4 months compared to 3.5 months for non-responders [10] - Safety data indicated that Komzifti was generally well tolerated, with most adverse reactions being grade one or two [11] Treatment Implications - Komzifti is positioned as a foundational therapy for acute leukemias, with ongoing studies exploring its use in frontline therapy and combinations with other treatments [5][18] - Approximately 20% of patients are refractory to frontline treatment, and 50% of those achieving complete remission will relapse, highlighting the urgent need for effective therapies [8] Commercial Strategy - Kura has prepared for the U.S. launch of Komzifti, with a launch price set at $48,500 for a one-month supply [28] - The U.S. market for NPM1-mutated relapsed refractory AML is estimated to be between $350 million and $400 million annually, with potential for a larger opportunity in frontline AML [29] - Kura's commercial strategy focuses on driving adoption, ensuring broad access, and leveraging partnerships, particularly with Kyowa Kirin [25][26] Market Dynamics - The company anticipates that Komzifti will become the preferred option in the relapsed refractory NPM1-mutated AML setting due to its best-in-class profile and ease of use [21][22] - Kura's field teams are targeting over 4,000 healthcare providers to maximize reach and impact [25] Future Developments - Ongoing trials are evaluating Komzifti in various treatment settings, including combinations with standard chemotherapy regimens [18][19] - The company is committed to generating robust clinical data to support Komzifti's adoption and integration into treatment guidelines [19] Safety and Drug Interactions - Komzifti does not require dosage reduction when administered with strong CYP3A4 inhibitors, enhancing its compatibility with supportive therapies [12][13] - The absence of significant drug-drug interactions is a key advantage over competing therapies [13][24] Conclusion - Kura Oncology is poised to transform AML treatment with Komzifti, supported by a strong clinical profile, strategic commercial plans, and a commitment to patient care [30]